PIN36 Six Years Observational Study of the Cost of Highly Active Antiretroviral Therapy and HIV/AIDS Control  by Dimitrova, M. et al.
data to calculate direct, indirect and intangible costs in patients receiving ART.
METHODS: Multicenter prospective observational study in eight German special-
ized centres for infectious diseases: four private practices/outpatient centres and
four hospitals offering inpatient- and outpatient facilities. CORSAR started recruit-
ment during 2009 and ends in July 2012, when the last patient reaches week 96.
After signing informed consent, patients were included and stratified by treatment
line. Treatment history and concomitant therapy were taken from the patients’
records. Direct costs for hospitalization, outpatient care, other medical care and
treatment as well as out of pocket payments and quality of life data were calculated
from the data collected by quarterly questionnaires. RESULTS: A total of 1154 pa-
tients with a mean age 47.5y receiving ART were included. Time since HIV-diagno-
sis was10.6 years, 10.2% had viral load50 cp/ml; 10.6% female; employment ratio
60.8%. Direct costs of treatment were mainly driven by antiretroviral drugs, ac-
counting for 83.3%. Due to use of less complex ART-regimens and more frequent
use of NNRTI-based ART in earlier treatment lines total costs were highest in ad-
vanced treatment-lines (3rd) with 26,243 €/year compared to 22,718 €/year for
initial therapy. The labour market participation rate also decreases with advance-
ment in treatment lines (65% in first treatment line vs. 46% in3rdtreatment lines).
Indirect cost due to productivity losses account for 7% of total costs.
CONCLUSIONS: Total costs were higher in later lines of therapy due to more com-
plex, less NNRTI-based regimens. In comparison to earlier studies the impact of
Non-ART-costs decreased. Expenses to be borne by the patient increased but are
still less than 1%, indicating an increasing financial burden of people living with
HIV by their disease within the German health system.
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OBJECTIVES: Prior trials have demonstrated efficacy and effectiveness of po-
saconazole in the prophylaxis of invasive fungal diseases (IFDs) in high-risk pa-
tients. Controversy exists about the cost effectiveness of posaconazole prophylaxis
in neutropenic patients with a high risk of IFDs. We performed an analysis com-
paring the direct costs of posaconazole prophylaxis against topical polyene
(thrush) prophylaxis in patients with acute myelogenous leukemia (AML) and my-
elodysplastic syndrome (MDS). METHODS: Data of AML/MDS patients receiving
remission-induction chemotherapy were analysed to compare hospital costs of
patients before (2003-05) and after (2006-08) introduction of posaconazole prophy-
laxis. All cases were part of an earlier analysis demonstrating effectiveness of
posaconazole over topical prophylaxis. Duration on general ward, intensive care
unit, mechanical ventilation, diagnostic procedures and all anti-infective drugs
were included into the cost analysis. RESULTS: Patient groups were well matched
according to age, gender, underlying disease, and duration of neutropenia. The
average costs per patient in the posaconazole group (n76) and the topical polyene
group (n81) were 21,040 € (95% CI: 18,204-23,876 €) and 23,169 € (95% CI: 19,402-
26,937 €) per patient, respectively. Antifungal treatment costs were nominally
higher in the posaconazole group (4,580 € [95% CI: 3,678-5,482 €] vs. 4,019 € [95% CI:
2,825-5,214 €]). Costs for antibacterials (1,316 € [95% CI: 1,039-1,593 €] vs. 1,533 € [95%
CI: 1,238-1,827 €]) were numerically decreased in the posaconazole group. Average
duration of ICU stays were 1.79 (95% CI: 0.68-2.90) days per patient compared to 3.83
(95% CI: 1.53-6.13) days per patient. Costs for diagnostic procedures were 611 € (95%
CI: 478-744 €) and 653 € (95% CI: 552-754 €) per patient, respectively. CONCLUSIONS:
In our hospital, there was a trend towards cost-saving by posaconazole prophylaxis
in patients receiving remission-induction chemotherapy. These cost savings were
primarily caused by a shorter overall length of stay and the less frequent ICU
treatment of patients receiving posaconazole.
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OBJECTIVES: To provide a general overview of antimicrobial prescribing cost in a
South African primary care patient population whose prescriptions were dis-
pensed by community pharmacies. METHODS: A retrospective, cross-sectional
pharmacoepidemiological study was conducted on prescription data of a national
community pharmacy group in South Africa for 2010. All records for antimicrobials
were analysed. The MIMS classification system was used. RESULTS: A total of 660
500 patients received 1 576 593 antimicrobial products during 2010 (average of 2.39
products per year) at a total cost of R191 875 007. The average age of patients was
34.23 years. Most patients were females (58.32%), and they were prescribed 60.12%
of antimicrobial products. The average cost per antimicrobial product was R121.70
(SDR158.21). Antiviral agents were the most expensive (R195.67), followed by ami-
noglycosides (R188.42). The least expensive products were chloramphenicols
(R17.25) and sulphonamides and combinations (R22.68). Beta-lactams were the
most often prescribed class accounting for 36.02% of all antimicrobial prescrip-
tions. The average cost for a beta-lactam prescription was R99.53. The average cost
per over-the-counter product was R32.75, compared to R158.21 for prescription-
only antimicrobials. Most products were tablets (61.80%), followed by capsules
(16.25%) and suspensions (14.39%). Per prescription, the injections were the most
expensive (average of R343.85 per prescription), followed by ampoules (R324.56)
and solutions (R267.33). Creams were on average the least expensive (R31.24).
There was a clear peak in prescribing during the winter months (May to August).
The single most often prescribed trade name product was a generic combination
product of amoxicillin and clavulanic acid. On average, the most expensive trade
name product was Valcyte 450R tablets (valganciclovir) at R12 217.76.
CONCLUSIONS: This study provided a general overview of antimicrobial prescrib-
ing cost in a South African primary care patient population. Costs varied hugely
with generic prescribing influencing costs.
PIN36
SIX YEARS OBSERVATIONAL STUDY OF THE COST OF HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY AND HIV/AIDS CONTROL
Dimitrova M1, Savova A1, Manova M1, Mitov K2, Stefanova M1, Petrova G3
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University Sofia,
Faculty of Pharmacy, Sofia, Sofia, Bulgaria, 3Medical University, Faculty of Pharmacy, Sofia,
Bulgaria
OBJECTIVES: To analyze the changes in the highly active antiretroviral pharmaco-
therapy during the period 2006-2011 and its impact on cost and disease control of
HIV/AIDS patients in Bulgaria. METHODS: It is a combined retrospective and pro-
spective observational real life study on cost and therapeutic results of AIDS pa-
tient’s therapy. Information was gathered for 2/3 of the treated patients for the
antiretroviral combinations therapy and its cost, CD4 count and viral load. The
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load were evaluated. Descriptive statistic, Willcoxon tests, and Spearman
correlation analysis were applied. RESULTS: On total 162 patients were included
and out of them 48 identified with the changes in their therapy. Nearly 40 different
dosage regimes were found prescribed as combinations of 3 or 4 medicines. During
the period were introduces 3 new antiretroviral medicines (tenofovir, emtricit-
abine, darunavir). The average yearly cost of pharmacotherapy is increasing from
155 837.64 euro to 319 571.76 euro during 2006 - 2011. To all treatment naive pa-
tients were prescribed the newly authorized medicines that lead to sustained sup-
pression of viral load to20 in 45.46%. Introduction of the new medicines led to the
increase in total pharmacotherapy cost with 291 89.64 euro, but also to better
disease control. Statistically significant were the changes in the mean cost of ther-
apy in 2007 vs 2006 (p0,0002) and in 2010 vs 2009 (p 0,0001). We found the
statistically significant changes among the mean cost of therapy and viral load
(p0,0221), as well as among the mean cost of therapy and CD4 count (p0,05). The
correlation among the therapeutic results and the therapeutic combinations were
found in 2011 (p0,0064).CONCLUSIONS:AIDS remain costly disease for the health
insurance budget but new medicines led to better control on its progression.
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OBJECTIVES: To estimate the impact of initial empiric antibiotic treatment failure
on pharmacological and total health care costs in hospitalized patients with cIAIs.
METHODS: The economic impact associated with initial empiric antibiotic treat-
ment failure was based on the results of an observational epidemiological study
involving 201 adults with cIAI in Greece (NCT00929643). An average per patient-per
day DRG value was estimated based on diagnosis at discharge and DRG mapping.
Daily cost was then extrapolated to the additional length of stay (LOS), associated
with initial antibiotic failure. Costs included expenditure for additional ICU and
surgical interventions. DRG matching was validated by a specialist medical advi-
sor. Mean per patient DRGs were weighed against subject percentage in each diag-
nosis group. Mean per patient costs for unsuccessful initial therapies were calcu-
lated using the latest formulary prices and the mean number of days on each
antibiotic agent, as recorded in the observational study. RESULTS: The most fre-
quently reported diagnoses (201 subjects) were perforation of the intestine (15.9%),
acute appendicitis with peritoneal abscess (13.4%) and post–operative peritonitis
(13.4%). Patients most commonly received metronidazole (59.2%), followed by
b–lactamase inhibitors (38.3%) and second generation cephalosporines (30.3%) as
empiric antibiotic treatment (as part of monotherapy, double therapy or triple
therapy schemes). 78 patients exhibited failure of the initial treatment, whereas
initial treatment was successful in 111 subjects with respective hospitalization of
21.916.4 and 8.9  4.5 days. Total additional per patient resource cost was esti-
mated to be €3,761.56 inclusive of unsuccessful mean empiric antibiotic expendi-
ture, which was estimated to be €220.06 per patient. CONCLUSIONS: Retrospective
data collected for a 2-year period showed that a significant percentage (42.9%) of
patients exhibited failure of their initial antibiotic treatment. These patients had a
greater chance of requiring prolongation of hospitalization and more extensive use
of health care expenditure during times where resources are scarce.
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